Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Potential antilipolytic activity of suloctidil

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Sulocton® [CP 556 S; 1-(4-isopropylthiophenyl)-2-n-octyl-amino-propanol], Continental Pharma S.A., Brussels, Belgium; Continental Pharma, Belgian Patents no739678 (1969) and no755688(1970)

  2. 2.

    Adriaensen, H.: Current Ther. Research (submitted)

  3. 3.

    Roba, J.,et al.: Continental Pharma report (to be published)

  4. 4.

    Roncucci, R.,et al.: ibid. Continental Pharma report

  5. 5.

    Peeters, H.,et al.: Nature (submitted)

  6. 6.

    Gillot, P.: unpublished data

  7. 7.

    Finger, K.F., Page, J.G., Feller, D.R.: Biochem. Pharmacol.15, 1023 (1966)

  8. 8.

    Blaton, V., Vandamme, D., Peeters, H.: FEBS Letters44, 185 (1974)

  9. 9.

    Duncombe, W.G.: Biochem. J.83, 6p (1962);88, 7 (1963); Clin. Chim. Acta8, 122 (1964)

  10. 10.

    Muller, D.W., Allen, D.D.: Soc. Exp. Biol. Med.136 (3), 711 (1971); Andersson, R.,et al.: Atherosclerosis18, 399 (1973); Blackard, W.G., Kokatnur, M.G.: J. Atheroscler. Res.8, 189 (1968)

  11. 11.

    Dole, V.P.: J. Clin. Invest.,35, 150 (1956)

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Roncucci, R., Roba, J., Lambelin, G. et al. Potential antilipolytic activity of suloctidil. Naturwissenschaften 62, 141 (1975). https://doi.org/10.1007/BF00623284

Download citation

Keywords

  • Antilipolytic Activity
  • Suloctidil